Cover Image
市場調查報告書

肺移植:開發中產品分析

Lung Transplantation - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 264100
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
肺移植:開發中產品分析 Lung Transplantation - Pipeline Review, H1 2016
出版日期: 2016年05月11日 內容資訊: 英文 57 Pages
簡介

肺移植是除去患有疾病的肺,換成捐贈者摘出的健康的肺的手術。有腦死肺移植,以及生體肺移植。

本報告提供肺移植相關藥物的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

肺移植概要

治療藥的開發

  • 開發中產品的概要

肺移植:企業開發中的治療藥

肺移植:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

肺移植:企業開發中的產品

肺移植的治療藥的開發企業

  • Apeptico Forschung und Entwicklung GmbH
  • Kamada Ltd.
  • Proteo, Inc.
  • Quark Pharmaceuticals, Inc.

肺移植:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肺移植:最近的開發平台趨勢

肺移植:暫停中的計劃

肺移植:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8056IDB

Summary

Global Markets Direct's, 'Lung Transplantation - Pipeline Review, H1 2016', provides an overview of the Lung Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lung Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplantation and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lung Transplantation
  • The report reviews pipeline therapeutics for Lung Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lung Transplantation therapeutics and enlists all their major and minor projects
  • The report assesses Lung Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lung Transplantation

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lung Transplantation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lung Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lung Transplantation Overview
  • Therapeutics Development
    • Pipeline Products for Lung Transplantation - Overview
  • Lung Transplantation - Therapeutics under Development by Companies
  • Lung Transplantation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Lung Transplantation - Products under Development by Companies
  • Lung Transplantation - Companies Involved in Therapeutics Development
    • Apeptico Forschung und Entwicklung GmbH
    • Kamada Ltd.
    • Proteo, Inc.
    • Quark Pharmaceuticals, Inc.
  • Lung Transplantation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FX-06 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PB-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • QPLI-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-503 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • solnatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tiprelestat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lung Transplantation - Recent Pipeline Updates
  • Lung Transplantation - Dormant Projects
  • Lung Transplantation - Product Development Milestones
    • Featured News & Press Releases
      • Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
      • Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
      • Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs
      • Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation
      • Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
      • Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Lung Transplantation, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Lung Transplantation - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2016
  • Lung Transplantation - Pipeline by Kamada Ltd., H1 2016
  • Lung Transplantation - Pipeline by Proteo, Inc., H1 2016
  • Lung Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Lung Transplantation Therapeutics - Recent Pipeline Updates, H1 2016
  • Lung Transplantation - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Lung Transplantation, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top